8-K current report · filed Nov 19, 2026

Tvardi Therapeutics, Inc. (TVRD) 8-K Current Report: November 19, 2026

Item 7.01Item EX-99.1TVRD overview

Short answer

Tvardi Therapeutics, Inc. (TVRD) filed an 8-K current report with the SEC on November 19, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). TTI-109 advanced toward an Investigational New Drug filing for inflammatory bowel disease.

Tvardi Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • TTI-109 advanced toward an Investigational New Drug filing for inflammatory bowel disease
  • FDA pre-IND feedback supports continued development of Tvardi’s next-generation oral STAT3 inhibitor
  • Milestone may reduce regulatory uncertainty, but clinical efficacy and safety remain unproven
  • Full program details and FDA feedback are in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • FDA pre-IND feedback supports Phase 2 development approach for TTI-109 in ulcerative colitis and Crohn’s disease
  • IND submission planned for 2027, with Phase 2 initiation contingent on FDA clearance and additional funding
  • Phase 1 exposure analysis supports sustained STAT3 inhibition at proposed doses with minimal predicted STAT1 and STAT5 effects
  • Potential differentiation from JAK inhibitors through narrower STAT3 targeting, though patient safety and clinical benefit remain unproven
  • Regulatory progress advances TTI-109 toward clinical testing but increases dependence on financing availability

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tvardi Therapeutics, Inc. 8-K filings

Get the next TVRD 8-K as it lands

Follow TVRD for push alerts, or ask the research agent what this filing means.